{"id":"bdp","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Oropharyngeal candidiasis"},{"rate":"1-5","effect":"Dysphonia"},{"rate":"1-3","effect":"Tremor"},{"rate":"2-5","effect":"Headache"},{"rate":"2-5","effect":"Throat irritation"}]},"_chembl":{"chemblId":"CHEMBL2325227","moleculeType":"Unknown","molecularWeight":"1099.99"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Beclomethasone dipropionate (BDP) is a topical corticosteroid delivered via inhalation that suppresses local inflammatory responses in the respiratory tract. It binds to glucocorticoid receptors on immune cells and epithelial cells, reducing the production of inflammatory mediators and decreasing airway hyperresponsiveness. The drug acts locally in the lungs with minimal systemic absorption when used at therapeutic doses.","oneSentence":"BDP is a inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in the lungs.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:45.434Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT07489911","phase":"","title":"Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)","status":"RECRUITING","sponsor":"Chiesi Slovenija, d.o.o.","startDate":"2024-11-04","conditions":"Asthma, Asthma Patients, Asthma Bronchiale","enrollment":200},{"nctId":"NCT06786767","phase":"","title":"Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting","status":"COMPLETED","sponsor":"Chiesi Bulgaria","startDate":"2025-02-01","conditions":"Asthma, Asthma Patients, Asthma Bronchiale","enrollment":281},{"nctId":"NCT01577082","phase":"PHASE3","title":"Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-04-20","conditions":"Asthma","enrollment":542},{"nctId":"NCT03963167","phase":"","title":"Triple Therapy in Real-life: Impact on Adherence and Health Status (TRITRIAL)","status":"COMPLETED","sponsor":"Chiesi Italia","startDate":"2019-08-21","conditions":"COPD","enrollment":661},{"nctId":"NCT05168995","phase":"","title":"Effects of Beclometasone Dipropionate/Formoterol Fumarate Via NEXT(Haler) in a Real-world Study on Asthma Control","status":"COMPLETED","sponsor":"Chiesi Italia","startDate":"2022-04-12","conditions":"Asthma","enrollment":620},{"nctId":"NCT07282886","phase":"PHASE2","title":"VENTURI (VENTilation Using Respiratory Imaging)","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-03-15","conditions":"Asthma","enrollment":20},{"nctId":"NCT07406048","phase":"","title":"Real-World Effectiveness of a Triple Combination BDP/FF/GB Extrafine in a Single Pressurised Metered Dose Inhaler in Brazilian COPD Patients","status":"NOT_YET_RECRUITING","sponsor":"Chiesi Farmaceutica Ltda.","startDate":"2026-01-30","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":396},{"nctId":"NCT04320342","phase":"PHASE3","title":"A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2022-04-28","conditions":"COPD, COPD Exacerbation","enrollment":3433},{"nctId":"NCT07357831","phase":"PHASE3","title":"A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2025-12-26","conditions":"Plaque Psoriasis","enrollment":537},{"nctId":"NCT07301736","phase":"PHASE2","title":"Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma","status":"RECRUITING","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2025-12-17","conditions":"Asthma","enrollment":780},{"nctId":"NCT06480890","phase":"","title":"Real-World Effectiveness of a Triple Combination BDP/FF/GB in a Single Pressurised Metered Dose Inhaler in COPD Patients (TRIPHY)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2024-07-02","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":362},{"nctId":"NCT06264674","phase":"PHASE3","title":"Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2023-11-27","conditions":"Asthma","enrollment":836},{"nctId":"NCT05811234","phase":"","title":"A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in Adults","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2023-06-13","conditions":"Plaque Psoriasis","enrollment":291},{"nctId":"NCT05743608","phase":"","title":"NEXThaleR Real-world Study Assessing the EffectivenesS of BDP/FF/G Fixed triPle cOmbiNation on Symptom scorEs in COPD Patients","status":"COMPLETED","sponsor":"Chiesi Hungary Ltd.","startDate":"2023-03-29","conditions":"COPD","enrollment":1336},{"nctId":"NCT06908421","phase":"","title":"Efficacy of a Smart add-on Device in Combination With a Triple Treatment in Asthma Patients on Inhaler Technique and Adherence","status":"RECRUITING","sponsor":"Chiesi Pharma AB, Nordic","startDate":"2025-09-15","conditions":"Asthma","enrollment":60},{"nctId":"NCT05292586","phase":"PHASE3","title":"A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2022-08-31","conditions":"Asthma","enrollment":1377},{"nctId":"NCT07099534","phase":"PHASE2","title":"Ketamine Infusion for Symptomatic Improvement in Severe Borderline Personality Disorder","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Toulouse","startDate":"2025-11-01","conditions":"Infusion of Ketamine in Severe Borderline Personality Disorder, Borderline Personality Disorder (BPD)","enrollment":38},{"nctId":"NCT06100042","phase":"","title":"Observational Study on Therapy Pathways of Asthamics Treated With ICS/LABA/LAMA Therapy in a Real-world Setting","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chiesi Italia","startDate":"2024-04-24","conditions":"Asthma","enrollment":200},{"nctId":"NCT05652439","phase":"","title":"PASS to Assess Cardiovascular and Cerebrovascular Events in COPD Patients Initiating Fixed Triple Therapy (DPI or pMDI)","status":"RECRUITING","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2022-12-02","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":25000},{"nctId":"NCT06869382","phase":"PHASE4","title":"ICS+LABA Vs. ICS+LABA+Omalizumab: Impact on Asthma Control and Gene Expression","status":"COMPLETED","sponsor":"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation","startDate":"2023-01-01","conditions":"Asthma Patients","enrollment":26},{"nctId":"NCT02132936","phase":"PHASE3","title":"LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2014-06","conditions":"Psoriasis Vulgaris","enrollment":504},{"nctId":"NCT01837576","phase":"PHASE1","title":"An Exploratory Psoriasis Plaque Test Study With Different Dose Combinations of Calcipotriol Plus Betamethasone Dipropionate in the Daivobet® Gel Vehicle in Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-04","conditions":"Psoriasis Vulgaris","enrollment":24},{"nctId":"NCT03308799","phase":"PHASE3","title":"A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2017-10-03","conditions":"Psoriasis Vulgaris","enrollment":794},{"nctId":"NCT03888131","phase":"PHASE3","title":"Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2018-07-30","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":750},{"nctId":"NCT06678191","phase":"","title":"Investigation of Fixed Triple Inhaled Combination in Asthmatic Patients, in a Real-life Setting","status":"RECRUITING","sponsor":"Chiesi Hungary Ltd.","startDate":"2024-10-24","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD), Asthma Bronchiale","enrollment":800},{"nctId":"NCT05898984","phase":"PHASE1","title":"Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2023-04-24","conditions":"Asthma","enrollment":69},{"nctId":"NCT05830071","phase":"PHASE1","title":"A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2023-03-29","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":95},{"nctId":"NCT02102711","phase":"NA","title":"Oral Vitamin A Supplementation in Neonates With Birth Weight < 1500 g","status":"COMPLETED","sponsor":"Francesca Garofoli","startDate":"2014-04","conditions":"Bronchopulmonary Dysplasia, Retinopathy of Prematurity","enrollment":62},{"nctId":"NCT05097014","phase":"PHASE4","title":"CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2021-10-28","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":106},{"nctId":"NCT03795350","phase":"PHASE1","title":"Lung Deposition of TRIMBOW® pMDI in Healthy Volunteers, Asthmatic and COPD Patients","status":"TERMINATED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2019-01-14","conditions":"Chronic Obstructive Pulmonary Disease, Asthma","enrollment":19},{"nctId":"NCT04873063","phase":"PHASE1","title":"Evaluation of Systemic Bioavailability and Effects on 24-Hour Plasma Cortisol Profile of 6 mg Delivered Once Daily Versus 3 mg Delivered Twice Daily in Healthy Adult Male Volunteers","status":"COMPLETED","sponsor":"SOFAR S.p.A.","startDate":"2021-10-22","conditions":"Healthy Adult Male Volunteers","enrollment":28},{"nctId":"NCT01615874","phase":"PHASE2","title":"Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574)","status":"WITHDRAWN","sponsor":"Organon and Co","startDate":"2013-01","conditions":"Asthma","enrollment":""},{"nctId":"NCT03855189","phase":"PHASE3","title":"Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Dipropionate or Placebo in Seasonal Allergic Rhinitis (C93-013)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1993-08-23","conditions":"Seasonal Allergic Rhinitis","enrollment":345},{"nctId":"NCT03879772","phase":"PHASE3","title":"Dose-Ranging Study of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (C95-161)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1996-03-12","conditions":"Rhinitis, Allergic, Seasonal","enrollment":679},{"nctId":"NCT04876677","phase":"PHASE3","title":"Functional Respiratory Imaging Study","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2021-05-25","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":25},{"nctId":"NCT03084718","phase":"PHASE2","title":"An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2017-07-28","conditions":"Asthma","enrollment":610},{"nctId":"NCT01024608","phase":"PHASE3","title":"Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2009-12-31","conditions":"Seasonal Allergic Rhinitis, Hay Fever","enrollment":340},{"nctId":"NCT00988247","phase":"PHASE3","title":"Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 mcg in Allergic Rhinitis","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2009-10-31","conditions":"Rhinitis, Allergic, Perennial","enrollment":529},{"nctId":"NCT05114434","phase":"","title":"Effect of BDP/Formoterol/G on Cough Efficacy in Moderate to Severe COPD Patients (EFFICACE)","status":"UNKNOWN","sponsor":"University of Parma","startDate":"2021-11","conditions":"COPD, Chronic Obstructive Pulmonary Disease","enrollment":40},{"nctId":"NCT02031640","phase":"PHASE3","title":"A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12","conditions":"Asthma","enrollment":1113},{"nctId":"NCT02040779","phase":"PHASE3","title":"A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12-26","conditions":"Persistent Asthma","enrollment":273},{"nctId":"NCT02040766","phase":"PHASE3","title":"A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12","conditions":"Asthma","enrollment":628},{"nctId":"NCT02000609","phase":"PHASE2","title":"A Phase II, 5-way Cross-over Study to Evaluate the Pharmacodynamics of \"Nexthaler\" Dry Powder Inhaler in COPD Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2013-12","conditions":"COPD","enrollment":49},{"nctId":"NCT00929851","phase":"PHASE3","title":"BDP/FF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2009-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1199},{"nctId":"NCT02287272","phase":"PHASE1","title":"Drug-drug Interaction Study of CHF5993 With Cimetidine","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2014-05","conditions":"COPD","enrollment":25},{"nctId":"NCT02467452","phase":"PHASE3","title":"Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2015-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1479},{"nctId":"NCT01917331","phase":"PHASE3","title":"Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2014-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1368},{"nctId":"NCT01343745","phase":"PHASE2","title":"Dose Response AMP Challenge Study With Beclometasone Dipropionate (BDP)/Formoterol Pressurised Metered Dose Inhaler (pMDI)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2008-02","conditions":"Mild Persistent Asthma","enrollment":18},{"nctId":"NCT01911364","phase":"PHASE3","title":"Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2014-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":3686},{"nctId":"NCT01176747","phase":"PHASE1, PHASE2","title":"Lung Deposition of the BDP/Formoterol Combination Administered Via the NEXT DPI in Healthy, Asthmatic and COPD Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2010-08","conditions":"Pulmonary Disease, Chronic Obstructive, Asthma","enrollment":28},{"nctId":"NCT02579850","phase":"PHASE3","title":"2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2015-05-29","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1532},{"nctId":"NCT01738087","phase":"PHASE2","title":"Lung Bioavailability and Total Systemic Exposure to Beclomethasone17MonoPropionate and Formoterol Across Two Strengths of NEXThaler Inhalation Powder","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-11","conditions":"Asthmatic","enrollment":30},{"nctId":"NCT01476813","phase":"PHASE2","title":"Randomized Cross Over Study to Assess Efficacy and Safety of BDP/FF and Glycopyrrolate","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":281},{"nctId":"NCT03859414","phase":"PHASE1","title":"PK of BDP/FF/GB Single-inhaler Triple Therapy in Japanese vs. Caucasians","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2019-03-18","conditions":"Asthma, Chronic Obstructive Pulmonary Disease","enrollment":32},{"nctId":"NCT03590379","phase":"PHASE2","title":"Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2018-06-15","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":366},{"nctId":"NCT02676076","phase":"PHASE3","title":"TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-02-17","conditions":"Asthma","enrollment":1153},{"nctId":"NCT02676089","phase":"PHASE3","title":"TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-04-06","conditions":"Asthma","enrollment":1433},{"nctId":"NCT03197818","phase":"PHASE3","title":"Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-12-14","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":990},{"nctId":"NCT03802344","phase":"PHASE3","title":"This Trial is a Randomised, Multicentre, Investigator-blind, Vehicle and Comparator-controlled, Parallel-group Trial With the Purpose of Evaluation Efficacy, Safety and Convenience of the MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2018-12-12","conditions":"Psoriasis Vulgaris","enrollment":498},{"nctId":"NCT01280175","phase":"PHASE1","title":"Foster With or Without Charcoal Block or Aerochamber Plus","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2006-12","conditions":"Healthy Volunteers","enrollment":13},{"nctId":"NCT01349257","phase":"PHASE2","title":"Pharmacokinetic Clinical Study of CHF1535 NEXT DPI® Versus CHF1535 pMDI","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2011-05","conditions":"Asthma","enrollment":24},{"nctId":"NCT01848769","phase":"PHASE2","title":"Clinical Pharmacology Study of CHF1535 pMDI 50/6 µg Versus The Free Combination In Asthmatic Children 5-11 Years Old","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2009-09","conditions":"Asthma","enrollment":20},{"nctId":"NCT01803087","phase":"PHASE2","title":"Single-Dose Clinical Pharmacology Study in Asthmatic Adolescent and Adult Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-02","conditions":"Asthma","enrollment":60},{"nctId":"NCT01191424","phase":"PHASE2","title":"A Study Comparing the Pharmacokinetic, Pharmacodynamic and Safety of CHF 1535 (Fixed Combination of Beclomethasone + Formoterol) Administered Via the NEXT DPI, Versus the Free Combination of Licenced Beclomethasone DPI and Formoterol DPI in Asthmatic Adolescent and Adult Patients.","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2010-10","conditions":"Asthma","enrollment":57},{"nctId":"NCT04421742","phase":"","title":"The Effect of Beclomethasone/Formoterol in Extra-fine Formulation on Quality of Life and SAD in COPD Patients.","status":"COMPLETED","sponsor":"Alfredo Antonio Chetta","startDate":"2017-05-31","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":43},{"nctId":"NCT03899064","phase":"PHASE1","title":"Evaluation of Potential Development of Photoallergic Skin Reaction After Use of MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2019-02-13","conditions":"Photoallergy","enrollment":58},{"nctId":"NCT03268226","phase":"PHASE3","title":"Functional Respiratory Imaging Study (FRI)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2017-11-20","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":20},{"nctId":"NCT03892564","phase":"PHASE1","title":"Evaluation of Potential Phototoxicity Skin Reaction After Use of MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2019-02-27","conditions":"Phototoxicity","enrollment":35},{"nctId":"NCT03462927","phase":"PHASE2","title":"A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2018-02-08","conditions":"Psoriasis Vulgaris","enrollment":63},{"nctId":"NCT02766673","phase":"NA","title":"Aerosolized Albuterol Use in Severe BPD","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2016-08","conditions":"Severe Bronchopulmonary Dysplasia","enrollment":24},{"nctId":"NCT00829257","phase":"PHASE4","title":"Additive Effects of QVAR to (Seretide) on Surrogate Markers of Airway Inflammation in Refractory Asthma","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2009-01","conditions":"Asthma","enrollment":15},{"nctId":"NCT00921921","phase":"PHASE4","title":"Does Extra-fine Hydrofluoroalkane-beclomethasone Dipropionate (HFA-BDP) Suppress Small Airways Inflammation in Chronic Obstructive Pulmonary Disease (COPD)?","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2009-06","conditions":"COPD","enrollment":16},{"nctId":"NCT01925950","phase":"PHASE2","title":"Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)","status":"TERMINATED","sponsor":"Soligenix","startDate":"2013-12","conditions":"Chronic Gastrointestinal Graft vs Host Disease","enrollment":2},{"nctId":"NCT03503994","phase":"NA","title":"Inhaled Corticosteroids for Treatment of Bronchopulmonary Dysplasia","status":"COMPLETED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2001-07-27","conditions":"Bronchopulmonary Dysplasia","enrollment":41},{"nctId":"NCT00862394","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2009-02","conditions":"Asthma","enrollment":783},{"nctId":"NCT02787967","phase":"PHASE2","title":"Clinical Pharmacology of 35/4 NEXThaler® in Children 5-11 Years Old","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-08","conditions":"Asthma","enrollment":26},{"nctId":"NCT02646904","phase":"PHASE4","title":"Nebulized Beclometasone Dipropionate Improves Nasal Patency in Children With Allergic Rhinitis","status":"COMPLETED","sponsor":"Stefania La Grutta, MD","startDate":"2016-05","conditions":"Allergic Rhinitis","enrollment":68},{"nctId":"NCT02975843","phase":"PHASE1","title":"Lung Deposition of Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-11-21","conditions":"Chronic Obstructive Pulmonary Disease, Asthma","enrollment":28},{"nctId":"NCT00528723","phase":"PHASE3","title":"Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2007-11","conditions":"Bronchial Asthma","enrollment":180},{"nctId":"NCT01351792","phase":"PHASE3","title":"A Study in Patients With Chronic Obstructive Pulmonary Disease (FAIR)","status":"TERMINATED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2011-09","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":113},{"nctId":"NCT01245569","phase":"PHASE3","title":"A Study in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2011-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":373},{"nctId":"NCT00862264","phase":"PHASE3","title":"Efficacy and Tolerability of Beclomethasone Dipropionate/Formoterol Single Inhaler in Patients With Mild to Moderate Persistent Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2004-08","conditions":"Asthma","enrollment":286},{"nctId":"NCT01345916","phase":"PHASE3","title":"Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2011-03","conditions":"Asthma","enrollment":932},{"nctId":"NCT00861926","phase":"PHASE3","title":"Study Comparing Foster Efficacy Maintenance and Reliever Versus Foster Maintenance + Salbutamol Reliever in Asthmatics","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2009-03","conditions":"Asthma","enrollment":2079},{"nctId":"NCT00868023","phase":"PHASE2","title":"Next DPI LABA, Multicentre, 5-way Cross-over, Adult Asthmatic Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2009-02","conditions":"Asthma","enrollment":69},{"nctId":"NCT01570478","phase":"PHASE3","title":"A Study in Patients With Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-07","conditions":"Asthma","enrollment":108},{"nctId":"NCT01475032","phase":"PHASE3","title":"Efficacy Study of the Product \"CHF 1535\" Versus Beclomethasone (BDP) and Free Combo in Asthmatic Children","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2011-09","conditions":"Asthma","enrollment":638},{"nctId":"NCT01584492","phase":"PHASE2","title":"Bronchodilator Effect of CHF1535 pMDI Versus Free Combination of Beclometasone Plus Formoterol pMDI in Asthmatic Children","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2011-12","conditions":"Asthma","enrollment":59},{"nctId":"NCT02381158","phase":"PHASE4","title":"Nebulized Beclomethasone Dipropionate Improves Respiratory Lung Function in Preschool Children With Recurrent Wheezing","status":"COMPLETED","sponsor":"Istituto per la Ricerca e l'Innovazione Biomedica","startDate":"2015-02","conditions":"Wheezing","enrollment":12},{"nctId":"NCT00659048","phase":"PHASE3","title":"Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients With Perennial Allergic Rhinitis (PAR) (BY9010/M1-408)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-12","conditions":"Rhinitis, Allergic, Perennial","enrollment":106},{"nctId":"NCT02671773","phase":"","title":"Characterising the Microbiota in Asthma","status":"COMPLETED","sponsor":"University of Nottingham","startDate":"2014-06","conditions":"Asthma","enrollment":72},{"nctId":"NCT01783548","phase":"PHASE3","title":"Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-01","conditions":"Allergic Rhinitis","enrollment":547},{"nctId":"NCT01697956","phase":"PHASE3","title":"Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Perennial Allergic Rhinitis (PAR)","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-10","conditions":"Allergic Rhinitis","enrollment":99},{"nctId":"NCT02526758","phase":"PHASE4","title":"Small Airways Evaluation and Treatment","status":"UNKNOWN","sponsor":"Zhujiang Hospital","startDate":"2015-04","conditions":"Pulmonary Disease，Chronic Obstructive;","enrollment":90},{"nctId":"NCT01650441","phase":"PHASE2","title":"Study to Assess the Effect of the NEXThaler® Device (DPI - Dry Powder Inhaler) on the Central and Peripheral Airway Dimensions in Asthmatic Patients","status":"COMPLETED","sponsor":"University Hospital, Antwerp","startDate":"2012-04","conditions":"Asthma","enrollment":31},{"nctId":"NCT01307319","phase":"PHASE3","title":"Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2011-03","conditions":"Seasonal Allergic Rhinitis, SAR","enrollment":715},{"nctId":"NCT01620099","phase":"PHASE4","title":"Small Airways Involvement in Smoker Asthmatic Patients: a Pilot Study","status":"COMPLETED","sponsor":"Università degli Studi di Ferrara","startDate":"2011-11","conditions":"Asthma","enrollment":60},{"nctId":"NCT01632540","phase":"","title":"Effectiveness of Beclomethasone Dipropionate Nasal Aerosol for Perennial Allergic Rhinitis","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-07","conditions":"Perennial Allergic Rhinitis (PAR)","enrollment":824},{"nctId":"NCT00926575","phase":"PHASE3","title":"Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)","status":"TERMINATED","sponsor":"Soligenix","startDate":"2009-10","conditions":"Acute Gastrointestinal Graft vs Host Disease","enrollment":140},{"nctId":"NCT01287351","phase":"","title":"Real-world Effectiveness and Cost-effectiveness of Qvar Versus FP, a US Study","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"2004-01","conditions":"Asthma","enrollment":82903}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ACTIVITIES OF DAILY LIVING IMPAIRED"},{"count":1,"reaction":"ASTHMA"},{"count":1,"reaction":"BODY TEMPERATURE DECREASED"},{"count":1,"reaction":"CENTRAL OBESITY"},{"count":1,"reaction":"CUSHING^S SYNDROME"},{"count":1,"reaction":"DECREASED APPETITE"},{"count":1,"reaction":"DISSEMINATED CRYPTOCOCCOSIS"},{"count":1,"reaction":"DISSEMINATED INTRAVASCULAR COAGULATION"},{"count":1,"reaction":"DRUG INTERACTION"},{"count":1,"reaction":"DRY MOUTH"}],"_approvalHistory":[],"publicationCount":2043,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["QNASL®","Beclomethasone dipropionate"],"phase":"phase_3","status":"active","brandName":"BDP","genericName":"BDP","companyName":"Teva Branded Pharmaceutical Products R&D, Inc.","companyId":"teva-branded-pharmaceutical-products-r-d-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BDP is a inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in the lungs. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}